Brii Biosciences Limited , a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, announced new in vitro pseudoviris neutralization data demonstrating that its amubarvimab/romlusevimab combination therapy (previously referred to as combination BRII-196/BRII-198) retains activity against the new Omicron SARS-CoV-2 variant.
Also Read: Ascend to expand compound production to Latin America
These data add to the growing body of evidence demonstrating that the amubarvimab/romlusevimab combination retains activity against key World Health Organization’s COVID-19 variants of concern, also including Delta (B.1.617.2) and Delta Plus (AY.4.2).
“We believe the amubarvimab/romlusevimab combination has the potential to be a best-in-class treatment option for a broad range of high risk COVID-19 patients. These latest findings underscore that our combination antibody therapy holds up well against the Omicron variant that pose a significant public health threat worldwide,” said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio. “As experts around the world continue to track Omicron and other variants of concern, independent labs have demonstrated that our combination therapy will continue to provide clinical benefits for both patients who present early for treatment and those who present late for treatment. We look forward to continuing our work with the U.S. FDA and regulatory authorities around the world to bring our combination therapy to patients in need as quickly as possible.”
The in vitro tests against pseudovirus from independent labs have demonstrated the Omicron variant remains susceptible to neutralization by the amubarvimab/romlusevimab combination. While there was substantial drop in activity for amubarvimab against the Omicron variant, romlusevimab was not impacted by the omicron variant.
“These new preclinical data provide further evidence of that the amubarvimab/romlusevimab combination provides significant benefits for high risk patients who contract the Omicron variant, given its highly successful track record thus far to reduce hospitalization and death among all tested variants of concern, including the Delta variant, ” said David Margolis, M.D., MPH, Vice President and Head of Infectious Diseases Therapy at Brii Bio.